Sotagliflozin attenuates liver associated disorders in cystic fibrosis rabbits

• DOI: 10.1172/jci.insight.165826
• Publication Date: 2024-02-15T17:00:16Z
• Authors: Xiubin Liang; Xia Hou; Mohamad Bouhamdan; Yifei Sun; Zhenfeng Song; Carthic Rajagopalan; Hong Jiang; Hong-Guang Wei; Jun Song; Dongshan Yang; Yanhong Guo; Yihan Zhang; Hongmei Mou; Jifeng Zhang; Y. Eugene Chen; Fei Sun; Jian-Ping Jin; Kezhong Zhang; Jie Xu

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene lead to cystic fibrosis (CF), a life-threating autosomal recessive genetic disease. While recently approved Trikafta dramatically ameliorates CF lung diseases, there is still a lack of effective medicine to treat CF-associated liver disease (CFLD). To address this medical need, we used a recently established CF rabbit model to test if Sotagliflozin, a Sodium-Glucose cotransporter 1 and 2 (SGLT1/2) inhibitor drug that is approved to treat diabetes, can be repurposed to treat CFLD. Sotagliflozin treatment led to systemic benefits to CF rabbits, evidenced by increased appetite and weight gain as well as prolonged lifespan. For CF liver related phenotypes, the animals benefited from normalized blood chemistry and bile acid parameters. Further, Sotagliflozin alleviated non-alcoholic steatohepatitis (NASH)-like phenotypes including liver fibrosis. Intriguingly, Sotagliflozin treatment markedly reduced the otherwise elevated endoplasmic reticulum (ER) stress responses in the liver and other affected organs of CF rabbits. In summary, our work demonstrates that Sotagliflozin attenuates liver disorders in CF rabbits, and merits Sotagliflozin as a potential drug to treat CFLD.